HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants [Phase 3]
Phase 3 clinical trial evaluating DTaP-IPV-HB-PRP-T as a primary series and a second-year booster in HIV-exposed infants (infected and uninf…
-
CLINICAL_TRIALS trial_result · 2022-04-01Clinical Trial Update: EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS [Phase 4]
Phase 4 trial evaluating a simplification strategy using dolutegravir and darunavir/cobicistat versus optimized treatment in suppressed HIV-…
-
FDA approval · 2022-03-31FDA Approved: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for Teva’s generic fixed-dose combination emtricitabine and tenofovir disoproxil fumarate. This …
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: Adolescent Transition To Adult Care for HIV-infected Adolescents in Kenya [NA]
Clinical trial update on transitioning HIV-infected adolescents in Kenya to adult care; study completed with results posted in 2022.
-
FDA approval · 2022-03-30FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) from ViiV Healthcare Company for…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-03-30FDA Approved: TRIUMEQ PD — Original Application (ViiV Healthcare Company)
FDA approved TRIUMEQ PD, a fixed-dose combination of abacavir, dolutegravir, and lamivudine, under an Original Application for pediatric pat…
-
FDA approval · 2022-03-29FDA Approved: EDURANT — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for EDURANT (rilpivirine hydrochloride) from Janssen Products, LP.
-
FDA approval · 2022-03-29FDA Approved: VOCABRIA — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for VOCABRIA (cabotegravir sodium) from ViiV Healthcare Company, enabling changes to the drug's …
-
FDA approval · 2022-03-29FDA Approved: CABENUVA — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for CABENUVA (cabotegravir and rilpivirine), an injectable HIV treatment from ViiV Healthcare Co…
-
CLINICAL_TRIALS trial_result · 2022-03-29Clinical Trial Update: Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use [NA]
A completed clinical trial studying how timing of ART initiation and alcohol use affect outcomes in early HIV infection.
-
FDA approval · 2022-03-23FDA Approved: VOCABRIA — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for VOCABRIA (cabotegravir sodium) from ViiV Healthcare Company.
-
CLINICAL_TRIALS trial_result · 2022-03-22Clinical Trial Update: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents [Phase 1, Phase 2]
This clinical trial update reports safety and immune response data for dolutegravir in HIV-1 infected infants, children, and adolescents fro…
-
FDA approval · 2022-03-21FDA Approved: LOPINAVIR AND RITONAVIR — Original Application (Laurus Labs Limited)
FDA approved an original application for a generic fixed-dose combination of lopinavir and ritonavir for HIV-1 infection, manufactured by La…
-
CLINICAL_TRIALS trial_result · 2022-03-07Clinical Trial Update: Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants [Phase 1]
Phase 1 study evaluating safety and pharmacokinetics of the HIV broadly neutralizing antibody VRC07-523LS in healthy, HIV-uninfected adults;…
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Sustainable East Africa Research in Community Health [NA]
Clinical trial update from a UCSF-sponsored study completed in 2022, focusing on HIV and tuberculosis with additional conditions listed in t…
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: The Development of a Mobile-based App to Increase Uptake of Pre-Exposure Prophylaxis (PrEP) by Men Who Have Sex With Men in China [NA]
Clinical trial update on a mobile app designed to increase PrEP uptake among men who have sex with men in China; completed with results post…
-
CLINICAL_TRIALS trial_result · 2022-02-22Clinical Trial Update: Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM [Phase 4]
Phase 4 clinical trial update examining persistence of antiretroviral therapy in different body compartments among HIV-negative men who have…
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection [Phase 3]
Phase 3 pharmacokinetic and safety study in pregnant women with HIV completed; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-02-11Clinical Trial Update: Neurocognitive Effects of Opiate Agonist Treatment [Phase 4]
Phase 4 clinical trial update examining neurocognitive effects of opiate agonist treatment in opioid-related disorders with HIV co-occurrenc…
-
CLINICAL_TRIALS trial_result · 2022-02-11Clinical Trial Update: Zinc Supplementation and Cardiovascular Risk in HIV [NA]
A completed clinical trial investigating zinc supplementation and cardiovascular risk in HIV patients; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-02-09Clinical Trial Update: Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals [Phase 1]
Phase 1 trial evaluating combination therapy with 3BNC117 and 10-1074 in HIV-infected individuals was terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-02-08Clinical Trial Update: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women [Phase 2]
Phase 2 trial evaluating VRC01 antibody for reducing acquisition of HIV-1 infection in women has completed; results posted.
-
CLINICAL_TRIALS trial_result · 2022-02-08Clinical Trial Update: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men [Phase 2]
Phase 2 trial evaluating VRC01 antibody to reduce acquisition of HIV-1 infection among men and transgender women who have sex with men; stud…
-
FDA approval · 2022-02-07FDA Approved: VOCABRIA — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for VOCABRIA (cabotegravir sodium) filed by ViiV Healthcare Company under NDA 212887.
-
FDA approval · 2022-02-07FDA Approved: CABENUVA — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for CABENUVA (cabotegravir and rilpivirine) from ViiV Healthcare Company, resulting in changes t…